June 4, 2020 / 1:30 PM / a month ago

BRIEF-Heron Therapeutics Says Primary And Key Secondary Endpoints In Study 209 Achieved

June 4 (Reuters) - Heron Therapeutics Inc:

* HERON THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM STUDY 209, A PHASE 2B STUDY OF HTX-011 IN PATIENTS UNDERGOING TOTAL KNEE ARTHROPLASTY

* HERON THERAPEUTICS INC - ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN STUDY 209 WERE ACHIEVED

* HERON THERAPEUTICS INC - HTX-011 DEMONSTRATED STATISTICALLY SIGNIFICANT REDUCTIONS IN PAIN INTENSITY FOLLOWING SURGERY IN STUDY 209

* HERON THERAPEUTICS INC - HTX-011 WAS WELL TOLERATED IN STUDY 209, WITH A SAFETY PROFILE COMPARABLE TO PLACEBO AND BUPIVACAINE SOLUTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below